Company / Shareholders' Equity
IOVANCE BIOTHERAPEUTICS, INC. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$698.6M
FY2025
5-year range
$499.6M / $710.4M
FY2021-FY2025
Trend
-1.7%
vs FY2024
Sector context
#65 of 213
Health Care
What the data says
At $699M, IOVANCE BIOTHERAPEUTICS, INC.'s shareholders' equity ranks #65 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from $45M in FY2016 to $710M in FY2024.
Based on SEC 10-K filings.
$699M in FY2025 with a 5-year CAGR of +1.3%.
Improved from $585M to $699M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +11.8%
- 5-Year CAGR
- +1.3%
- 10-Year CAGR
- -
Sector benchmark
#65 of 213 in Health CareTop 31% of 213This company $698.6M Sector average $2.5B
▼
-72.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.3%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 1.7% year-over-year.
- Ranks #65 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $698.6M | -1.7% |
| FY2024 | $710.4M | +21.5% |
| FY2023 | $584.6M | +17.0% |
| FY2022 | $499.6M | -19.6% |
| FY2021 | $621.7M | -5.3% |
| FY2020 | $656.5M | +119.6% |
| FY2019 | $299.0M | -35.9% |
| FY2018 | $466.2M | +220.4% |
| FY2017 | $145.5M | +224.4% |
| FY2016 | $44.8M | +154.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026